Oramed Pharma (ORMP) Completes ORMD-0901 Phase 1b; No Serious Adverse Events Noted

November 29, 2016 8:32 AM EST
Get Alerts ORMP Hot Sheet
Trade ORMP Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) announced it successfully concluded a Phase Ib study of ORMD-0901, the Company's proprietary oral GLP-1 analog. The Phase Ib study on type 2 diabetic patients showed ORMD-0901 to be safe and well tolerated, having no serious adverse events, adverse events or abnormal laboratory findings during the study. In addition, the active oral GLP-1 arms of the study showed encouraging trending efficacy.

"We are very pleased with both the safety and efficacy results observed during this study. Currently we are preparing to submit an IND with the FDA and anticipate initiating a Phase IIb study in 2017," said Oramed CEO Nadav Kidron.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, FDA

Add Your Comment